Trial
NCT05678959
Long-term Extension Study of Ligelizumab in Food Allergy
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Food Allergy
Intervention
Ligelizumab 120 mg
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-13